News
RVVTF
0.026
+11.30%
0.003
Revive Therapeutics Grants 15.5 Million Stock Options to Key Team Members
TipRanks · 22h ago
Revive Therapeutics Reports Grant of Options
Barchart · 1d ago
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Barchart · 3d ago
Weekly Report: what happened at RVVTF last week (0803-0807)?
Weekly Report · 5d ago
Weekly Report: what happened at RVVTF last week (0727-0731)?
Weekly Report · 08/03 09:51
Weekly Report: what happened at RVVTF last week (0720-0724)?
Weekly Report · 07/27 09:54
Weekly Report: what happened at RVVTF last week (0713-0717)?
Weekly Report · 07/20 09:51
BlackRock Disclosure Confirms Significant Stake in Caledonia Mining
TipRanks · 07/16 11:24
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Barchart · 07/15 17:40
Weekly Report: what happened at RVVTF last week (0706-0710)?
Weekly Report · 07/13 09:53
Weekly Report: what happened at RVVTF last week (0629-0703)?
Weekly Report · 07/06 09:55
Weekly Report: what happened at RVVTF last week (0622-0626)?
Weekly Report · 06/29 09:52
Revive Therapeutics plans up to $1M private placement
Seeking Alpha · 06/26 20:46
Revive Therapeutics Announces Proposed Private Placement
Barchart · 06/26 15:15
Weekly Report: what happened at RVVTF last week (0615-0619)?
Weekly Report · 06/22 09:58
Weekly Report: what happened at RVVTF last week (0608-0612)?
Weekly Report · 06/15 09:59
Weekly Report: what happened at RVVTF last week (0601-0605)?
Weekly Report · 06/08 09:56
Weekly Report: what happened at RVVTF last week (0525-0529)?
Weekly Report · 06/01 09:59
Weekly Report: what happened at RVVTF last week (0518-0522)?
Weekly Report · 05/25 10:01
Revive expands bucillamine program across infectious diseases
TipRanks · 05/20 11:57
More
Webull provides a variety of real-time RVVTF stock news. You can receive the latest news about Revive Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About RVVTF
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for infectious diseases and medical countermeasures. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. The Company is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).